Viridian Therapeutics, Inc.\DE Business Summary

Viridian Therapeutics, Inc. (VRDN) is a clinical-stage biopharmaceutical company transitioning toward a commercial-stage entity, primarily focused on developing best-in-class therapies for thyroid eye disease (TED) and Graves' disease. The company’s business model centers on the discovery and engineering of monoclonal antibodies for previously validated drug targets, generating revenue through strategic royalty agreements, milestone payments, and anticipated commercial sales following the potential mid-2026 U.S. launch of its lead candidate, veligrotug (VRDN-001). Its primary business segments are categorized by therapeutic mechanism: the IGF-1R inhibitor portfolio (veligrotug and the subcutaneous elegrobart) and a burgeoning FcRn inhibitor pipeline (VRDN-006 and VRDN-008) targeting autoimmune indications. Viridian competes directly with Amgen (Tepezza), argenx (Vyvgart), and Roche (Enspryng), positioning itself as a high-convenience disruptor by offering subcutaneous self-administration and superior dosing intervals compared to established intravenous incumbents. The company is led by President and CEO Steve Mahoney, who joined in late 2023 with a pedigree in scaling biotech firms, having previously served as CFO and COO of Magenta Therapeutics and as a founding executive at Kiniksa Pharmaceuticals. The broader leadership team includes CFO Seth Harmon, CMO Dr. Radhika Tripuraneni, and Chief Technical Operations Officer Kyle Haraldsen, collectively bringing decades of experience from organizations like Alexion and Genzyme. While the company originated from the 2020 pivot of miRagen Therapeutics—founded by Vahe Bedian—its current strategic direction is heavily influenced by its board and major institutional backers, most notably Fairmount Funds Management LLC. Key board members include Fairmount founding partner Tomas Kiselak and Sarah Gheuens, CMO of Agios Pharmaceuticals, ensuring a leadership structure deeply rooted in specialized life sciences investment and clinical development.